StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) stock

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$27.93−0.08 (-0.29%)

Close on Nov 16, 2026Market cap $1.82BP/E –Yield –

Zenas BioPharma operating margin

Operating margin is operating income as a percentage of revenue.

Zenas BioPharma's operating margin for the twelve months ending Dec 31, 2025 was -3830.6%. For fiscal 2025 it was -3830.6%, against -3277.8% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-3830.6%−552.8
FY2024Dec 31, 2024-3277.8%−3203.5
FY2023Dec 31, 2023-74.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-1034.1%−1105.3
Q2 FY2026Jun 30, 2026-10765.9%–
Q1 FY2025Mar 31, 2025-373.3%–
Q4 FY2024Dec 31, 2024-1112.5%–
Q3 FY2023Sep 30, 202371.2%–

More Zenas BioPharma figures

See a number that looks wrong?